Liljas B, Lindgren B
Lund University Centre for Health Economics, Sweden.
Pharmacoeconomics. 2001;19(4):323-35. doi: 10.2165/00019053-200119040-00001.
For practical reasons, in order to carry out economic evaluations of collective decisions, total costs will generally be compared with total benefits; hence, individuals' willingness to pay (WTP) or quality-adjusted life-years (QALYs) have to be estimated at an aggregate level. So far, aggregation has usually been done by taking the individuals' mean WTP or the unweighted number of QALYs. Since the aggregation process is closely related to the way that income, health and/or utility of different individuals are compared and weighted, it also has significant equity implications. Thus. the explicit (or, more often, implicit) assumptions behind the aggregation process will largely affect how health and welfare are distributed is society. The aggregation problem in economic evaluation is certainly not trivial, but is seldom addressed in current practice. This paper shows the underlying assumptions of aggregate cost-benefit analysis (CBA) and cost-effectiveness analysis/cost-utility analysis (CEA/CUA), and it emphasises the particularly strong assumptions which have to be made when QALYs are interpreted as utilities in the welfare economics sense. Naturally, the appropriate method to choose depends on what is to be maximised: welfare or health. If decisions of resource allocation are to be based on economic welfare theory, then CBA should be preferred. However, if QALYs are interpreted as measures of health, rather than as utilities, then CEA/CUA would be appropriate.
出于实际原因,为了对集体决策进行经济评估,通常会将总成本与总收益进行比较;因此,必须在总体层面估计个人的支付意愿(WTP)或质量调整生命年(QALY)。到目前为止,汇总通常是通过计算个人的平均支付意愿或未加权的质量调整生命年数量来完成的。由于汇总过程与比较和加权不同个人的收入、健康和/或效用的方式密切相关,因此它也具有重大的公平性影响。因此,汇总过程背后的明确(或者更常见的是隐含)假设将在很大程度上影响健康和福利在社会中的分配方式。经济评估中的汇总问题绝非微不足道,但在当前实践中很少得到解决。本文阐述了总体成本效益分析(CBA)以及成本效果分析/成本效用分析(CEA/CUA)的潜在假设,并强调了在将质量调整生命年解释为福利经济学意义上的效用时必须做出的特别强烈的假设。当然,选择合适的方法取决于要最大化的是什么:福利还是健康。如果资源分配决策要基于经济福利理论,那么应该首选成本效益分析。然而,如果将质量调整生命年解释为健康指标,而不是效用指标,那么成本效果分析/成本效用分析将是合适的。